Related Experiment Video
Updated: May 7, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
6.9K
Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines
Minerva Anestesiologica
|October 15, 2013
Summary
Anesthesiologists must recognize cardiovascular toxicities from chemotherapy, including older anthracyclines and newer agents. Understanding type I and type II cardiotoxicity is crucial for perioperative management of cancer patients.
Area of Science:
- Cardiology
- Oncology
- Anesthesiology
Background:
- Chemotherapy agents can cause significant cardiovascular toxicities, including heart failure and hypertension.
- Anthracyclines (type I cardiotoxicity) are well-known for their cardiac effects.
- Newer chemotherapeutics like trastuzumab and bevacizumab also induce cardiotoxicity (type II), with different pathogenesis.
Purpose of the Study:
- To review current clinical evidence on chemotherapy-induced cardiovascular toxicity.
- To provide insights into the perioperative management of patients experiencing these toxicities.
Main Methods:
- Literature review of clinical evidence on cardiovascular toxicity from chemotherapeutic agents.
- Analysis of pathogenesis and clinical features of type I and type II cardiotoxicity.
Main Results:
- Cardiovascular toxicities are a significant concern in cancer patients undergoing chemotherapy.
- Distinct mechanisms underlie cardiotoxicity from anthracyclines versus newer agents.
- Awareness of specific clinical features for each cardiotoxicity type is essential.
Conclusions:
- Anesthesiologists require updated knowledge on chemotherapy-induced cardiovascular toxicities.
- Effective perioperative management strategies are needed for cancer patients with cardiotoxicity.
- Differentiating between type I and type II cardiotoxicity is key for patient care.
Related Concept Videos
02:49Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
937
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
937
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
829
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
829
01:00Drug Toxicity: Overview
313
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
313
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
01:24Drug Toxicity: Risk factors
250
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
250